In this cohort study of 5287 men with prostate cancer in the Million Veteran Program, the HSD3B1 adrenal-permissive homozygous genotype (compared with the adrenal-restrictive homozygous and heterozygous genotype) was associated with worse prostate cancer–specific mortality. This evidence concerns the gene HSD3B1 and prostate carcinoma.